FORM PTO-1595 1-31-92 (modified)

RECORDATION FORM COVER SHEET

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

PATENTS ONLY

Aventis Docket No. A2513E

To the Honorable Commissioner of Patents and Trademarks.	Please record the attached original documents or copy thereof.
1. Name of conveying party(ies); Rhône-Poulenc Rorer Pharmaceuticals Inc.	Name and address of receiving party(ies):
Additional name(s) of conveying party(ies) attached? \(\text{YES} \text{ NO} \) 3. Nature of Conveyance; Assignment	Name: Aventis Pharmaceuticals Products Inc. Internal Address: Street Address: Route 202-206 EMC-G1 City: Bridgewater State: NJ ZIP: 08807 Additional name(s) and address(es) attached? YES NO
Application number(s) or patent number(s): If this document is being filed together with a new application, the exect A. Patent Application No.(s): 09/453,307	cution date of the application is: B. Patent No.(s):
AddItional numbers attached?	
AZSI3E-US	6. Total number of applications and patents involved: 1 7. Total (37 CFR 3.41):
DO NOT USE THIS SPACE 3. Statement and signature.	
To the best of my knowledge and belief, the foregoing information is true document. rving Newman, Reg. No. 22,638 Name of Person Signing	and correct and any attached copy is a true copy of the original
MB No. 0651-0011 (exp. 4/94)	Oate: 10/23/00 \ Total number of pages comprising cover sheet: 1

Do not detach this portion

Mail documents to be recorded with required cover sheet information to: Commissioner of Patents and Trademarks

Commissioner of Patents and Tragemarks
Box Assignments
Washington, D.C. 20231
Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per Public burden reporting for this sample cover sneet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office. Office Information Systems, PK2-1000C, Washington, D.C. 20231, and to the Office of Management and Budget, Paperwork Reduction Project (0561-0011), Washington,

> **PATENT REEL: 011062 FRAME: 0539**

State of Delaware

PAGE 1

Office of the Secretary of State

I, EDWARD J. FREEL, SECRETARY OF STATE OF THE STATE OF

DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT

COPY OF THE CERTIFICATE OF AMENDMENT OF "RHONE-POULENC RORER

PHARMACEUTICALS INC.", CHANGING ITS NAME FROM "RHONE-POULENC

RORER PHARMACEUTICALS INC." TO "AVENTIS PHARMACEUTICALS PRODUCTS

INC.", FILED IN THIS OFFICE ON THE FIFTEENTH DAY OF DECEMBER,

A.D. 1999, AT 11:30 O'CLOCK A.M.

ward J. Freel, Secretary of State

DATE:

0631221 8100

UTHENTICATION:

0527106

001328622

የልቸደክየ

REEL: 011062 FRAME: 0540

CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF RHONE-POULENC RORER PHARMACEUTICALS INC.

The undersigned, being officers of Rhône-Poulenc Rorer Pharmaceuticals Inc. (the "Company"), for the purpose of amending the Certificate of Incorporation pursuant to the provisions of Sections 228 and 242 of the Delaware General Corporation Law, hereby execute the following Certificate of Amendment:

FIRST: The name of the corporation is RHONE-POULENC RORER PHARMACEUTICALS INC.

SECOND: The following amendment was adopted by the directors and sole shareholder in the manner prescribed by the Delaware General Corporation Law:

Article FIRST of the Certificate of Incorporation is hereby amended to read as follows:

"The name of the corporation is Aventis Pharmaceuticals Products Inc."

IN WITNESS WHEREOF, the undersigned have caused this Certificate of Amendment of the Certificate of Incorporation to be duly executed by its Senior Vice President and attested by its Assistant Secretary this 15th day of December, 1999.

RHÔNE-POULENC RORER PHARMACEUTICALS INC.

John R. Leone

Senior Vice President & General Manger

PATENT REEL: 011062 FRAME: 0541

RECORDED: 10/23/2000